Harrow Health engages in the development, production and sale of medications. Co. owns and operates an ophthalmic pharmaceutical businesses, ImprimisRx. Through its subsidiary, Melt Pharmaceuticals, Inc., Co. focuses on the development and commercialization of proprietary non-intravenous, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. Co.'s subsidiary, Surface Ophthalmics, Inc., focuses on development and commercialization of therapeutics for ocular surface diseases. Co. also has a business called Visionology, which is a membership-based online eye health and medication platform. The HROW stock yearly return is shown above.
The yearly return on the HROW stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the HROW annual return calculation with any dividends reinvested as applicable (on ex-dates).
|